Taconic Biosciences' Dr. Azusa Tanaka penned this article in Genetic Engineering & Biotechnology News about advancing In Vivo NK Cell studies by utilizing Precision Research Models:
"As the field of immunotherapy progresses, and more effective treatments reach patients, the use of live cells to attack tumors has become the next area of focus. While checkpoint inhibitors such as anti PD-1, PD-L1, and CTLA-4 have demonstrated they are capable of increasing T-cell activation--leading to enhanced antitumor responses--and FDA approvals have paved the way for chimeric antigen receptor T-cell (CAR-T) therapies, both approaches require sufficient T cells to stimulate or modify. That can prove challenging when a patient is immunosuppressed from a first-line therapy that affects T cells."
Read the complete article at: Genengnews.com
"As the field of immunotherapy progresses, and more effective treatments reach patients, the use of live cells to attack tumors has become the next area of focus. While checkpoint inhibitors such as anti PD-1, PD-L1, and CTLA-4 have demonstrated they are capable of increasing T-cell activation--leading to enhanced antitumor responses--and FDA approvals have paved the way for chimeric antigen receptor T-cell (CAR-T) therapies, both approaches require sufficient T cells to stimulate or modify. That can prove challenging when a patient is immunosuppressed from a first-line therapy that affects T cells."